T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Objectives:
1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and
non-myelo-ablative ablative stem cell transplantation in patients with hematologic
malignancies.
2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based
in vivo T-cell depletion, in patients with hematologic malignancies undergoing
non-myelo-ablative stem cell transplantation.
3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion
and non-myelo-ablative ablative stem cell transplantation in patients with hematologic
malignancies.